Invasive Fungal Infections clinical trials

The registry lists 136 studies for Invasive Fungal Infections across more than 10 countries. 33 are recruiting or about to start. 92 of them are mainly about Invasive Fungal Infections (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-12. Counting its 4 narrower conditions too, such as Candidemia: 296 studies, 50 open.

Get an email when these change. Save the Invasive Fungal Infections studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies

See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Status

Completed: 74
Recruiting: 20
Status unknown: 19
Not yet recruiting: 10
Terminated: 8
Enrolling by invitation: 2

Phase

Phase 3: 18
Phase 4: 16
Phase 2: 14
Phase 1: 10

Where

China: 29
United States: 24
France: 22
Spain: 14
Germany: 14
Belgium: 13

Who runs them

Radboud University Medical Center (7) · Pfizer (7) · Astellas Pharma Inc (5) · Merck Sharp & Dohme LLC (4) · Institute of Hematology & Blood Diseases Hospital, China (4) · University Hospital, Lille (3) · Basilea Pharmaceutica (3) · Asan Medical Center (3)

Who develops what

Save this set

Every programme with a company-led study here in the last two years, whatever its size: 3 programmes from 1 company, 3 with this as their studies’ main aim; 0 with a live phase 3 study; 0 primary completions in the next 12 months.

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

Drug	Leading trial sponsor · rights	Companies, last 5 years	Live now	Given as
olorofimRecent, limited Evidence NCT07712484 · F2G Ltd · Phase 2 · live · comparator · “Olorofim” · registered Jul 2026	F2G Biotech GmbH94% of its industry studies	11 study	11 study	comparator 1
FluconazoleEarlier only Evidence NCT04368559 · Mundipharma · Phase 3 · comparator · “Fluconazole” · registered Apr 2020 NCT03667690 · Merck & Co., Inc · Phase 3 · comparator · “Fluconazole” · registered Aug 2018 NCT01058174 · Astellas Pharma Inc · Phase 3 · comparator · “fluconazole” · registered Jan 2010	Pfizer59% of its industry studiesUS: off-patent, 11 generics marketed	00 studies	00 studies	comparator 3

Programmes

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

The 3 programmes — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (0)

Live phase 2 and 3 studies of these programmes. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

None in the next 12 months.

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorised original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licences, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Invasive Fungal Infections studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug	Open	Phase 3	All
Amphotericin B	1	3	8
Micafungin	1	2	8
Posaconazole	1	2	5
Oxygen	1	0	1
Caspofungin	0	2	5
Voriconazole	0	3	5
Liposomal amphotericin B	0	2	4
Isavuconazole	0	2	4
Olorofim	0	1	3
Itraconazole	0	0	3

Coming up

0phase 3 studies under way

9studies finish main data collection within a year

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

All 9

Dec 2026FungiScope - A Global Emerging Fungal Infection Registry · University of Cologne
Dec 2026Study on the Pharmacokinetic Characteristics of Liposomal Amphotericin B in Patients With Invasive Fungal Infections Undergoing Plasma Exchange Therapy · Institute of Hematology & Blood Diseases Hospital, China
Dec 2026Liposomal Amphotericin B and Isavuconazole/Posaconazole in Br-IFD（ Breakthrough Invasive Fungal Disease） in Patients With Malignant Hematological Diseases · Institute of Hematology & Blood Diseases Hospital, China
Feb 2027Low-Dose Liposomal Amphotericin B for Invasive Fungal Infection Prophylaxis in Neutropenic Children · Haikou Affiliated Hospital of Central South University Xiangya School of Medicine
Feb 2027A Real-world Prospective Observational Study on the Efficacy and Safety of L-AmB(Liposomal Amphotericin B) for br- IFD(Breakthrough Invasive Fungal Disease) in Children and Adolescent Patients With Hematological Malignancies Receiving Triazoles or Echinocandins Prophylaxis · Institute of Hematology & Blood Diseases Hospital, China
Mar 2027Posaconazole (MK-5592) Intravenous and Oral in Children (<2 Years) With Invasive Fungal Infection (MK-5592-127) · Merck Sharp & Dohme LLC
Apr 2027Immunomonitoring of Mold Invasive Infections · Assistance Publique - Hôpitaux de Paris
Sep 2027mNGS for IFD in Patients With Hematological Malignancies · Nanfang Hospital, Southern Medical University
Oct 2027Breath Analysis for the Detection of Invasive Fungal Infections · University of Zurich

Who these studies take

Of the 20 Invasive Fungal Infections studies recruiting now, 12 (60%) set no upper age limit and 5 (25%) stop at 75 or younger. 9 (45%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 2 (10%) take healthy volunteers.

Recruiting studies that take each age, of 20
Age	Women	Men
10	8 (40%)	8 (40%)
18	18 (90%)	18 (90%)
30	17 (85%)	17 (85%)
40	17 (85%)	17 (85%)
50	17 (85%)	17 (85%)
65	16 (80%)	16 (80%)
75	16 (80%)	16 (80%)
85	15 (75%)	15 (75%)

Across all 136 studies, recruiting or not: 26% stop at 75 or younger and 23% at 65; 40% take children; 1% are for women only and 2% for men only; 10% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Invasive Fungal Infections studies take

Of 30 observational studies under Invasive Fungal Infections, half reached primary completion within 37 months of starting, counting those still running.

Start to primary completion	Every sponsor	Industry	Non-industry
Observational	37 mo18–57 · 30 studies	—	—

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

Studies

Recruiting first, then most recently updated. Showing 50 of 136. Browse all 136 → or search them.